这是一项第三期、随机、双盲、安慰剂对照、多中心研究，评估 durvalumab 对比安慰剂作为巩固治疗，用于局部晚期、不可切除的非小细胞肺癌（第三期）患者，这些患者在接受确定性铂类化放疗后未出现疾病进展。

适应症：Carcinoma, Non-Small-Cell Lung

入组条件

Age≥18 years
Documented NSCLC and present with locally advanced, unresectable (Stage III) disease;
Receipt of concurrent or sequential chemoradiation therapy,
No progression following definitive, platinum-based, concurrent or sequential chemoradiation therapy
World Health Organization (WHO) PS of 0 or 1;
No prior exposure to any anti CTLA-4, anti-PD-1, anti-PD-L1, or anti PD L2 antibodies, excluding therapeutic anticancer vaccines
Adequate organ and marrow function required
Life expectancy of at least 12 weeks
Tumor PD-L1 status, with the Ventana SP263 PD-L1 IHC assay determined by a reference laboratory, must be known prior to randomization.
Tumour sample requirements are as follows: Provision of a tumour tissue sample (newly acquired sample \<=3 months old is preferred, but an archived sample \<=6 months old is acceptable) in a quantity sufficient to allow for analysis.

History of allogeneic organ transplantation, or another primary malignancy, or active primary immunodeficiency.
Active or prior documented autoimmune or inflammatory disorders
Uncontrolled intercurrent illness that would limit compliance with study requirement, substantially increase risk of incurring AEs, or compromise the ability of the patient to give written informed consent
Active infection including tuberculosis hepatitis B hepatitis C (HCV), or human immunodeficiency virus (positive human immunodeficiency virus \[HIV\] 1/2 antibodies).
Mixed small cell and NSCLC histology, sarcomatoid variant
Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 from the prior chemoradiation therapy.
Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.
Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.

入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。

Durvalumab 作为非小细胞肺癌患者巩固治疗的研究